Contract award notice
Results of the procurement procedure
Section I: Contracting
authority
I.1) Name and addresses
The NHS Commissioning Board (Operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
UK
E-mail: philip.grieve@nhs.net
NUTS: UK
Internet address(es)
Main address: https://nhsengland.bravosolution.co.uk
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders.
Reference number: CM/PHS/15/5498
II.1.2) Main CPV code
33141530
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.
II.1.6) Information about lots
This contract is divided into lots:
Yes
II.1.7) Total value of the procurement
Value excluding VAT:
302 000 000.00
GBP
II.2) Description
Lot No: 1
II.2.1) Title
Band 1.
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please see below.
II.2.4) Description of the procurement
NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.
II.2.5) Award criteria
Quality criterion: Available on request
/ Weighting: Available on request
Cost criterion: Price
/ Weighting: 85 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Band 2a.
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please see below.
II.2.4) Description of the procurement
NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.
II.2.5) Award criteria
Quality criterion: Available on request
/ Weighting: Available on request
Cost criterion: Price
/ Weighting: 85 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Band 2b
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please see below.
II.2.4) Description of the procurement
NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.
II.2.5) Award criteria
Quality criterion: Available on request
/ Weighting: Available on request
Cost criterion: Price
/ Weighting: 85 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
Band 3.
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please see below.
II.2.4) Description of the procurement
NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England, Scotland, Wales and Northern Ireland and may be used by private sector contractors and agents working on behalf of the above. The framework will commence on 1.2.2018 for a period of 12 months until 31.1.2019, with options to extend up to a further 17 months. Please refer to the invitation of Offer documents for the list of Purchasing Points.
II.2.5) Award criteria
Quality criterion: Available on request
/ Weighting: Available on request
Cost criterion: Price
/ Weighting: 85 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2017/S 158-326843
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
24/11/2017
V.2.2) Information about tenders
Number of tenders received: 5
Number of tenders received by electronic means: 5
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
For details of the awarded supplier see Section V1.2
Runcorn
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 302 000 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
The suppliers selected to participate in this framework agreement are:
— Baxalta Limited,
— Bayer Plc,
— Novo Nordisk Limited,
— Octapharma Limited,
— Pfizer Limited.
VI.4) Procedures for review
VI.4.1) Review body
The NHS Commissioning Board (Operating under the name of NHS England)
2nd Floor, Rutland House
Runcorn
UK
Telephone: +44 1928755245
VI.5) Date of dispatch of this notice
12/12/2017